HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

lotrafiban

Also Known As:
(S)-2,3,4,5-tetrahydro-4-methyl-3-oxo-7-((4-(4-piperidyl)piperidino)carbonyl)-1H-1,4-benzodiazepine-2-acetic acid, monohydrochloride; SB 214857; SB-214857; SB214857; lotrafiban hydrochloride
Networked: 6 relevant articles (1 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Granett, J: 3 articles (04/2001 - 06/2000)
2. Samuels, R: 3 articles (04/2001 - 06/2000)
3. Chan, R: 2 articles (08/2000 - 06/2000)
4. Graffagnino, C: 2 articles (08/2000 - 06/2000)
5. Topol, E J: 2 articles (08/2000 - 06/2000)
6. Amarenco, Pierre: 1 article (07/2003)
7. Blockade of the Glycoprotein IIb/IIIa Receptor to Avoid Vascular Occlusion Trial Investigators: 1 article (07/2003)
8. Califf, Robert M: 1 article (07/2003)
9. Davis, Stephen: 1 article (07/2003)
10. Diener, Hans-Christophe: 1 article (07/2003)

Related Diseases

1. Infarction (Infarctions)
2. Coronary Thrombosis
3. Stroke (Strokes)
4. Unstable Angina
11/01/2000 - "Lotrafiban (SmithKline Beecham) is a member of the latest generation of orally-active platelet GPIIb/IIIa blockers undergoing Phase III clinical trials to test the relative effectiveness versus other oral platelet inhibitors for ischaemic conditions including unstable angina, restenosis after PCI and stroke. "
11/01/2000 - "Preliminary results of the clinical trial APLAUD (antiplatelet useful dose) show that lotrafiban is clinically safe and well-tolerated in patients with recent myocardial infarction, unstable angina, transient ischaemic attack (TIA), or stroke when added to aspirin therapy. "
04/01/2001 - "Our objective was to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of lotrafiban, an oral glycoprotein IIb/IIIa inhibitor, in patients with a recent myocardial infarction, unstable angina, transient ischemic attack, or stroke. "
06/01/2000 - "Lotrafiban at doses of up to 50 mg twice daily was well-tolerated in a 12-week, double-blind, placebo-controlled, dose-ranging study in patients with recent myocardial infarction, unstable angina, transient ischemic attack, or stroke when added to aspirin therapy. "
06/01/2000 - "In the pivotal BRAVO study, lotrafiban therapy is being evaluated in patients who have had a recent myocardial infarction, unstable angina, transient ischemic attack, or ischemic stroke, or who present at any time after a diagnosis of peripheral vascular disease combined with either cardiovascular or cerebrovascular disease. "
5. Cerebrovascular Disorders (Cerebrovascular Occlusion)

Related Drugs and Biologics

1. lotrafiban
2. Clopidogrel (Plavix)
3. Platelet Aggregation Inhibitors (Antiplatelet Drugs)
4. Aspirin (Acetylsalicylic Acid)
5. tetrachloroisophthalonitrile (Bravo)
6. Platelet Membrane Glycoproteins
7. Glycoproteins (Glycoprotein)
8. Creatinine
9. 2'- deoxythymidylyl- (3'- 5')- 2'- deoxyadenosine (d(AT))

Related Therapies and Procedures

1. Therapeutics
2. Secondary Prevention